(NASDAQ:MGNX), ROCKVILLE, MD, Nov. 25, 2025 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, at […]
(NasdaqGM:NUKK), NEW YORK and TEL AVIV, Israel, Nov. 25, 2025 (GLOBE NEWSWIRE) — Nukkleus Inc. (NASDAQ: NUKK) (“Nukkleus” or the “Company”), a strategic acquirer and developer of high-potential businesses in the aerospace and defense (A&D) industry, today announced that it will hold a special meeting of stockholders on December 16, 2025, at 10:00 a.m. Eastern
(NASDAQ:FBLG), HOUSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the closing of its previously announced registered direct
(NASDAQ:AARD), SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) — Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the following conferences during December: Piper Sandler 37th Annual Healthcare Conference in New
(NASDAQ:CGON), IRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced two late breaking podium presentations on the topline results from BOND-003 Cohort P (BCG-Unresponsive in papillary-only) and first results
(NASDAQ:NDAQ), NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) — At the end of the settlement date of November 14, 2025, short interest in 3,414 Nasdaq Global MarketSM securities totaled 14,632,128,542 shares compared with 14,079,841,205 shares in 3,402 Global Market issues reported for the prior settlement date of October 31, 2025. The mid-October short interest represents
(NASDAQ:ZS), First Quarter Highlights Revenue grows 26% year-over-year to $788.1 million Annual Recurring Revenue (“ARR”) grows 26% year-over-year to $3,204 million Deferred revenue grows 32% year-over-year to $2,351.3 million GAAP net loss of $11.6 million compared to GAAP net loss of $12.1 million on a year-over-year basis Non-GAAP net income of $159.5 million compared to
(NYSE:OI), PERRYSBURG, Ohio, Nov. 25, 2025 (GLOBE NEWSWIRE) — O-I Glass, Inc. (“O-I Glass” or “O-I”) today announced the Company will participate in Citi's 2025 Basic Materials Conference on Wednesday, December 3, 2025. O-I Glass Chief Executive Officer Gordon Hardie and Chief Financial Officer John Haudrich will present at 11:30 a.m. ET. A live webcast
(NASDAQ:LENZ), SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ(TM) (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in
(NasdaqGM:CRML), NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) — Critical Metals Corp. (Nasdaq: CRML) (“Critical Metals Corp” or the “Company”), a leading critical minerals mining company, today announced that ECM Lithium AT GmbH has received the decision of the Federal Administrative Court in the appeal proceedings concerning the requirement for an environmental impact assessment (EIA)